Pfizer markets Vyndamax as the "only once-daily capsule". The evidence says otherwise.
Patients are not informed that a cheaper rival pill exists, or that Pfizer paid the support group it recommends.
Read full report →Original reporting on regulatory enforcement, PBM conduct and governance failures across the US pharmaceutical industry.
Patients are not informed that a cheaper rival pill exists, or that Pfizer paid the support group it recommends.
Read full report →A Florida federal court publicly released an order vacating a $48,362,033 arbitration award against OptumRx entities. The underlying decision was dated September 17.
The FTC's order changes how Cigna's pharmacy benefit manager behaves from here. It returns nothing for the years the agency says list prices were inflated.
State attorneys general sought approval of a generic-drug pricing settlement with Sandoz and Fougera. Illinois described approximately $469 million in total obligations, including $69 million for previously settling states.
Omnicare filed for bankruptcy two months after the judgment. The government now stands to collect less than half, and CVS admits nothing.
Florida filed a consumer-protection lawsuit against Pfizer and its chief executive. Pfizer disputed the allegations.
The largest distributor's share of the national settlement runs for 18 years. None of it goes to individual patients.
CMS finalised the GLOBE drug-payment model, with initial reporting in January 2027 and its performance period beginning April 2027. The rule is a payment-policy measure, not an enforcement finding against manufacturers.
Pharmacy benefit managers are paid more when list prices and rebates are higher. Two FTC settlements and a federal reform law have not yet changed that, and Pfizer's contracts stay secret.
A New York federal judge dismissed Rxeed's antitrust and contractual-interference claims against Caremark. A claim concerning prospective business relationships remains pending.
The company reported itself and got credit for it. The admissions it signed show how the arrangement was built around the launch of Oxervate.
A West Virginia federal judge ordered arbitration of Fruth's claims against OptumRx and Caremark. Claims against Express Scripts were severed and transferred to Missouri.
The company admitted paying doctors hundreds of thousands of dollars each. It still describes the programs as education.
Twelve Arkansas pharmacies filed a private lawsuit against Express Scripts in Missouri state court, alleging reimbursements below Arkansas's statutory minimum. They seek damages and court-ordered changes; the filing establishes no liability.
The settlement includes no admission. Cigna's review found unsupported codes and it left them in place, the government said.
The Sixth Circuit reversed an order returning Kentucky's opioid lawsuit against Express Scripts and OptumRx to state court. The ruling addressed jurisdiction, without deciding liability.
The Anti-Kickback Statute bars paying doctors to prescribe. It still permits paying them to talk about the same drug, and patients never see who was paid.
The Justice Department announced that Remedi SeniorCare Holding Corporation agreed to pay more than $5.3 million to the United States over allegedly invalid prescription claims. The settlement is based on ability to pay and provides for installment payments without an admission of liability.
The FTC closed its insulin case against CVS's pharmacy benefit manager with conduct terms the company says it largely follows already.
The Justice Department announced a settlement with Abbott Laboratories over allegedly noncompliant infant formula and nutritional products purchased through government programs. Abbott denied the allegations and did not admit facts or liability.